Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MeiraGTx Holdings

DB:328
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
328
DB
$488M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • MeiraGTx Holdings has significant price volatility in the past 3 months.
328 Share Price and Events
7 Day Returns
2.7%
DB:328
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:328
-7.4%
DE Biotechs
-14.2%
DE Market
328 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MeiraGTx Holdings (328) 2.7% -15.6% -38.4% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 328.
  • No trading data on 328.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is MeiraGTx Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MeiraGTx Holdings. This is due to cash flow or dividend data being unavailable. The share price is €11.4.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MeiraGTx Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MeiraGTx Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:328 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.65
NasdaqGS:MGTX Share Price ** NasdaqGS (2020-04-08) in USD $13.25
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MeiraGTx Holdings.

DB:328 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MGTX Share Price ÷ EPS (both in USD)

= 13.25 ÷ -1.65

-8.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeiraGTx Holdings is loss making, we can't compare its value to the Europe Biotechs industry average.
  • MeiraGTx Holdings is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MeiraGTx Holdings's expected growth come at a high price?
Raw Data
DB:328 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-11.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MeiraGTx Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MeiraGTx Holdings's assets?
Raw Data
DB:328 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.19
NasdaqGS:MGTX Share Price * NasdaqGS (2020-04-08) in USD $13.25
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:328 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MGTX Share Price ÷ Book Value per Share (both in USD)

= 13.25 ÷ 5.19

2.55x

* Primary Listing of MeiraGTx Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeiraGTx Holdings is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess MeiraGTx Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MeiraGTx Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MeiraGTx Holdings expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-11.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MeiraGTx Holdings expected to grow at an attractive rate?
  • Unable to compare MeiraGTx Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare MeiraGTx Holdings's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • MeiraGTx Holdings's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:328 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:328 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -11.8%
DB:328 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 49.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:328 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:328 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 89 11 -103 2
2023-12-31 1 -48 -143 2
2022-12-31 0 -49 -121 2
2021-12-31 9 -48 -100 3
2020-12-31 9 -46 -95 3
2020-04-09
DB:328 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 13 20 -55
2019-09-30 6 31 -70
2019-06-30 3 38 -75
2019-03-31 1 41 -86
2018-12-31 -59 -85
2018-09-30 -51 -73
2018-06-30 -44 -66
2018-03-31 -29 -42
2017-12-31 -18 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MeiraGTx Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • MeiraGTx Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:328 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from MeiraGTx Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:328 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.25 -0.34 -4.15 2.00
2023-12-31 -3.28 -1.66 -4.90 2.00
2022-12-31 -2.91 -1.66 -4.15 2.00
2021-12-31 -2.41 -1.76 -3.40 3.00
2020-12-31 -1.90 -1.49 -2.50 3.00
2020-04-09
DB:328 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.65
2019-09-30 -2.29
2019-06-30 -2.62
2019-03-31 -3.58
2018-12-31 -4.47
2018-09-30 -5.04
2018-06-30 -6.64
2018-03-31 -4.84
2017-12-31 -3.72

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MeiraGTx Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MeiraGTx Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MeiraGTx Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MeiraGTx Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MeiraGTx Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MeiraGTx Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare MeiraGTx Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MeiraGTx Holdings's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MeiraGTx Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MeiraGTx Holdings Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:328 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 13.29 -54.75 46.68 24.88
2019-09-30 6.35 -70.32 41.17 38.16
2019-06-30 2.77 -75.29 37.92 41.65
2019-03-31 0.78 -85.59 41.86 39.67
2018-12-31 -84.67 44.48 33.62
2018-09-30 -72.78 37.71 28.61
2018-06-30 -65.99 33.45 26.89
2018-03-31 -42.08 18.30 24.46
2017-12-31 -31.85 9.33 22.36
2016-12-31 -19.57 6.03 14.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MeiraGTx Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MeiraGTx Holdings has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MeiraGTx Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MeiraGTx Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MeiraGTx Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MeiraGTx Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MeiraGTx Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MeiraGTx Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MeiraGTx Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MeiraGTx Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 7.5711102080935E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MeiraGTx Holdings Company Filings, last reported 3 months ago.

DB:328 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 190.80 0.00 227.23
2019-09-30 194.89 0.00 253.33
2019-06-30 129.56 0.00 204.27
2019-03-31 144.42 0.00 227.28
2018-12-31 81.06 0.00 68.08
2018-09-30 96.34 0.00 88.56
2018-06-30 108.47 0.00 102.06
2018-03-31 36.44 0.00 32.36
2017-12-31 3.97 1.44 8.55
2016-12-31 15.69 0.00 17.48
  • MeiraGTx Holdings's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if MeiraGTx Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making MeiraGTx Holdings has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making MeiraGTx Holdings has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -55.3% per year.
X
Financial health checks
We assess MeiraGTx Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MeiraGTx Holdings has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MeiraGTx Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MeiraGTx Holdings dividends.
If you bought €2,000 of MeiraGTx Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MeiraGTx Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MeiraGTx Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:328 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:328 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MeiraGTx Holdings has not reported any payouts.
  • Unable to verify if MeiraGTx Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MeiraGTx Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MeiraGTx Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MeiraGTx Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MeiraGTx Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MeiraGTx Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MeiraGTx Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alexandria Forbes
COMPENSATION $22,998,522
AGE 54
TENURE AS CEO 5.1 years
CEO Bio

Dr. Alexandria Forbes, Ph.D. serves as the Chief Executive Officer and President at MeiraGTx Limited since 2015. Prior to joining MeiraGTx, Dr. Forbes served as Senior Vice President of Strategic Operations and Chief Commercial Officer at Kadmon from 2013 to 2015 and served as its Director until May 25, 2018. She served as Managing Director of Sivik Global Healthcare, LLC. Dr. Forbes spent 10 years as a healthcare investor at Sivik/Argus Partners. At Sivik Partners Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and was portfolio manager for the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. She serves as Director of MeiraGTx Limited. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and it’s signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and her M.A. in Natural Sciences from Cambridge University, UK.

CEO Compensation
  • Alexandria's compensation has increased whilst company is loss making.
  • Alexandria's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MeiraGTx Holdings management team in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the MeiraGTx Holdings management team is less than 2 years, this suggests a new team.
Management Team

Alexandria Forbes

TITLE
CEO, President & Director
COMPENSATION
$23M
AGE
54
TENURE
5.1 yrs

Richard Giroux

TITLE
COO & CFO
COMPENSATION
$22M
AGE
45
TENURE
1 yrs

Stuart Naylor

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
56
TENURE
5 yrs

Elizabeth Broder

TITLE
Vice President of Investor Relations
TENURE
1.3 yrs

Robert Wollin

TITLE
Senior Vice President of Legal
TENURE
0.7 yrs

Micah Zajic

TITLE
Vice President of Corporate Development

Greg Petsko

TITLE
Chief Scientist & Chairman of Scientific Advisory Board

Robin Ali

TITLE
Head of Preclinical Ophthalmology & Member of Scientific Advisory Board

Michel Michaelides

TITLE
Head of Clinical Ophthalmology

Christine Sheehy

TITLE
Senior Vice President of Global Integration
Board of Directors Tenure

Average tenure and age of the MeiraGTx Holdings board of directors in years:

4.8
Average Tenure
68.5
Average Age
  • The tenure for the MeiraGTx Holdings board of directors is about average.
Board of Directors

Keith Harris

TITLE
Independent Chairman of the Board
COMPENSATION
$156K
AGE
66
TENURE
2.2 yrs

Alexandria Forbes

TITLE
CEO, President & Director
COMPENSATION
$23M
AGE
54
TENURE
5.1 yrs

Greg Petsko

TITLE
Chief Scientist & Chairman of Scientific Advisory Board

Robin Ali

TITLE
Head of Preclinical Ophthalmology & Member of Scientific Advisory Board

Joel Marcus

TITLE
Independent Director
COMPENSATION
$97K
AGE
71
TENURE
4.8 yrs

Tom Shenk

TITLE
Independent Director & Member of Scientific Advisory Board
COMPENSATION
$118K
AGE
72

Arnie Levine

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$88K
AGE
79
TENURE
4.2 yrs

Neil Mendoza

TITLE
Independent Director
COMPENSATION
$94K
AGE
59
TENURE
4.8 yrs

Scott Small

TITLE
Member of Scientific Advisory Board

Michael Kaplitt

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Nov 19 Buy Nicole Seligman Individual 19. Nov 19 19. Nov 19 5,000 €14.72 €73,599
20. Aug 19 Buy Perceptive Advisors LLC Company 12. Aug 19 12. Aug 19 425,531 €20.94 €8,908,981
X
Management checks
We assess MeiraGTx Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MeiraGTx Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson’s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson’s program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren’s syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company’s proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.

Details
Name: MeiraGTx Holdings plc
328
Exchange: DB
Founded: 2015
$448,615,261
36,817,916
Website: http://www.meiragtx.com
Address: MeiraGTx Holdings plc
430 East 29th Street,
14th Floor,
New York,
New York, 10016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MGTX Ordinary Shares Nasdaq Global Select US USD 08. Jun 2018
DB 328 Ordinary Shares Deutsche Boerse AG DE EUR 08. Jun 2018
Number of employees
Current staff
Staff numbers
157
MeiraGTx Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:21
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/11
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.